Cough – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cough – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Fluticasone Propionate and Amoxicillin-Clavulanic Acid for Children with Long-Lasting Cough https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-fluticasone-propionate-and-amoxicillin-clavulanic-acid-for-children-with-long-lasting-cough/ Wed, 29 Apr 2026 15:05:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-fluticasone-propionate-and-amoxicillin-clavulanic-acid-for-children-with-long-lasting-cough/ This clinical trial is focused on studying children with a protracted cough, which is a cough that lasts for an extended period without any other underlying health issues. The study will evaluate the effectiveness of two treatments: an inhaled medication called Fluticasone Propionate, which is a type of corticosteroid, and an oral antibiotic known as Amoxicillin and Clavulanic Acid. These treatments will be compared to a placebo to see how well they work in reducing the cough.

The purpose of the study is to determine if these medications can help children who have a persistent dry or wet cough. Participants will be randomly assigned to receive either the inhaled corticosteroid, the oral antibiotic, or a placebo. The study will be conducted in a double-blinded manner, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps ensure that the results are unbiased and reliable.

Throughout the study, the children’s cough symptoms will be monitored to see if there is a significant reduction in their cough. The study will last for a specific period, with the inhaled corticosteroid treatment lasting up to eight weeks and the oral antibiotic treatment lasting up to two weeks. The goal is to find out if these treatments can significantly reduce the cough symptoms in children compared to the placebo.

]]> Study on the Effectiveness of Amoxicillin and Clavulanic Acid in Treating Chronic Wet Cough in Young Children https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-amoxicillin-and-clavulanic-acid-in-treating-chronic-wet-cough-in-young-children/ Wed, 29 Apr 2026 15:05:44 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-amoxicillin-and-clavulanic-acid-in-treating-chronic-wet-cough-in-young-children/ The study focuses on young children who have a persistent cough that produces mucus, known as a chronic wet cough. The treatment being tested is a medication called Augmentin, which is a combination of two substances: amoxicillin and clavulanic acid. These substances work together to fight bacterial infections. The study will compare the effects of this medication to a placebo, which looks like the medication but does not contain any active ingredients.

The purpose of the study is to see if children with a chronic wet cough improve more when they take Augmentin for 14 days compared to those who take a placebo. Additionally, the study will explore whether extending the treatment to 28 days affects the time it takes for the cough to return. The study will also look at how the bacteria in the airways and gut, as well as inflammation and genetics, might influence the cough and its treatment.

Participants in the study will receive either the medication or the placebo for a set period. Researchers will monitor the children’s symptoms and any changes in their cough. The study will also examine the presence of bacteria and viruses, the diversity of bacteria in the airways and gut, and markers of inflammation in the body. The goal is to understand how these factors relate to the cough and its treatment, and to assess the overall quality of life for the children involved.

]]> Study on the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) for Adults with Refractory or Unexplained Chronic Cough https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-taplucainium-inhalation-powder-noc-110-for-adults-with-refractory-or-unexplained-chronic-cough/ Wed, 29 Apr 2026 15:02:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-taplucainium-inhalation-powder-noc-110-for-adults-with-refractory-or-unexplained-chronic-cough/ This clinical trial is focused on studying a condition known as Refractory or Unexplained Chronic Cough, which is a persistent cough that lasts for a long time without a clear cause or does not respond to usual treatments. The study is testing a new treatment called Taplucainium Inhalation Powder, also known by its code name NOC-110. This medication is taken by inhaling a powder through a device called a Monodose Dry Powder Inhaler. The purpose of the study is to evaluate how effective and safe this treatment is for adults who have this type of chronic cough.

Participants in the study will be randomly assigned to receive either the Taplucainium Inhalation Powder or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for 28 days, during which participants will take the treatment once daily. The study will test three different dose levels of the medication: 1 mg, 3 mg, and 6 mg. Researchers will monitor how often participants cough over a 24-hour period to see if the treatment reduces cough frequency.

Throughout the study, participants will be asked to report any side effects they experience. The study will also assess changes in how severe the cough feels and the urge to cough, using simple scales and questionnaires. The goal is to determine if Taplucainium Inhalation Powder can help reduce the symptoms of chronic cough and improve the quality of life for those affected by this condition.

]]> Study on the Effectiveness and Safety of Camlipixant for Adults with Refractory or Unexplained Chronic Cough https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-camlipixant-for-adults-with-refractory-or-unexplained-chronic-cough/ Wed, 29 Apr 2026 15:00:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-camlipixant-for-adults-with-refractory-or-unexplained-chronic-cough/ This clinical trial is focused on studying a condition known as Refractory Chronic Cough, which includes cases of Unexplained Chronic Cough. This condition is characterized by a persistent cough that does not respond to standard treatments. The trial will evaluate a new treatment called BLU-5937, which contains the active substance Camlipixant. Participants in the study will receive either BLU-5937 or a placebo, which is a substance with no active medication, to compare the effects on cough frequency and safety.

The purpose of the study is to assess how effective BLU-5937 is in reducing the frequency of coughing over a 24-hour period in adults with this chronic cough condition. The study will also monitor the safety of BLU-5937 over a period of 24 weeks. Participants will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment during the study period. This is known as a double-blind study, which helps ensure unbiased results.

The study will last for 24 weeks, with an additional open-label extension phase where all participants may receive BLU-5937. During the study, participants will have regular check-ups to monitor their health and any changes in their cough frequency. The study aims to provide valuable information on the potential benefits and safety of BLU-5937 for people suffering from refractory or unexplained chronic cough.

]]> Study on the Effects of Camlipixant in Adults with Refractory or Unexplained Chronic Cough https://clinicaltrials.eu/trial/study-on-the-effects-of-camlipixant-in-adults-with-refractory-or-unexplained-chronic-cough/ Wed, 29 Apr 2026 14:59:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-camlipixant-in-adults-with-refractory-or-unexplained-chronic-cough/ This clinical trial is focused on studying a condition known as Refractory Chronic Cough, which includes cases of Unexplained Chronic Cough. This condition is characterized by a persistent cough that does not respond to standard treatments and has no identifiable cause. The trial will evaluate a new treatment called BLU-5937, which contains the active substance Camlipixant. This medication is taken in the form of a tablet.

The purpose of the study is to assess the effectiveness and safety of BLU-5937 compared to a placebo in reducing the frequency of coughing over a 24-hour period. Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will last for 52 weeks, with an option for participants to continue in an open-label extension, where all participants can receive BLU-5937 if they choose.

Throughout the study, participants will be monitored to ensure their safety and to track any changes in their cough frequency. The study aims to provide valuable information on how well BLU-5937 works in managing chronic cough and its safety profile over the course of the treatment period.

]]>